Drug Profile

SUVN I6107

Alternative Names: SUVN-I6107

Latest Information Update: 24 Jan 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Suven Life Sciences
Class Antidementias
Mechanism of Action Muscarinic M1 receptor modulators

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Phase I Alzheimer's disease

Most Recent Events

07 Jan 2025 Phase-I clinical trials in Alzheimer's disease (In volunteers) in USA (PO) (NCT06705088)
04 Dec 2024 SUVN I6107 is still in preclinical trials in Alzheimer's-disease in India (PO)
26 Nov 2024 Suven Life Sciences plans a phase I trial for Alzheimer's disease (In volunteers) in USA (PO, Tablet) in December 2024 (NCT06705088)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com